Quarterly ResultMay 7, 2026, 04:21 PM
Definium Therapeutics Q1 Net Loss $77.1M; Cash $373.4M; 3 Phase 3 Readouts
AI Summary
Definium Therapeutics reported its first quarter 2026 financial results, with a net loss of $77.1 million, significantly higher than the $23.3 million loss in the prior year. The company maintained a strong financial position with $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, projected to fund operations into 2028. Operationally, Definium achieved significant progress, completing enrollment for its Phase 3 Emerge (MDD) and Voyage (GAD) studies, and expanding its DT120 ODT clinical development program into PTSD with the planned initiation of the Phase 3 Haven study in 2027. The company anticipates three pivotal data readouts for DT120 ODT within the next five months.
Key Highlights
- Definium Therapeutics reported a Q1 2026 net loss of $77.1 million, compared to $23.3 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $373.4 million as of March 31, 2026.
- The company expects its cash to fund operations into 2028.
- Research and Development expenses increased to $41.5 million in Q1 2026 from $23.4 million in Q1 2025.
- General and Administrative expenses rose to $17.7 million in Q1 2026 from $8.8 million in Q1 2025.
- Completed enrollment in Phase 3 Emerge (MDD) with 149 participants and Voyage (GAD) with 214 participants.
- Expanded DT120 ODT program into PTSD with Phase 3 Haven study expected to initiate in 2027.
- Three Phase 3 topline data readouts for DT120 ODT are expected in the coming five months.